Trump Drug Pricing Deals Face First Test as New Launches Reveal List Prices

Seventeen pharmaceutical manufacturers that signed most-favored-nation pricing agreements with the Trump administration are beginning to launch new products, providing the first public test of whether these voluntary commitments will constrain launch prices. The agreements, which pledge U.S. list prices will not exceed prices in other developed nations, lack formal enforcement mechanisms and apply only to new products launched after signing. For Medicaid managed care organizations, these launches will reveal whether rebate strategies and supplemental rebate negotiations need adjustment, particularly if launch prices come in lower than historical benchmarks would predict.

Pharmacy · Managed Care